Houston expert: Houston should focus on developing the region's life sciences sector

guest column

Houston needs to work on developing its life sciences infrastructure, like what the TMC3 project is providing. Courtesy of Elkus Manfredi Architects

The region's health care sector has been Greater Houston's job growth engine over the past few decades — creating new jobs at a rate 75 percent greater than the overall economy — according to research published last month in Center for Houston's Future report, Houston's Economic Future: Health Care.

But data from the Bureau of Economic Analysis and Bureau of Labor suggest that in many ways the economic footprint of our health care sector is not in line with the share of employment that health care commands across the region: While health care accounts for about 12 percent of the region's jobs, it is responsible for just 5.4 percent of Greater Houston's total gross domestic product.

By comparison, our energy sector holds roughly the same share of GDP as health care, but employs about just a fifth the number of employees.

To bridge this gap, Houston should focus on developing the region's life sciences sector, a promising economic development area with a potentially high economic payoff.

The life sciences represent a trillion-dollar plus global industry spanning pharmaceutical development, medical device manufacturing, research and commercialization of biotechnology and more. The employment multiplier — a measure of the economic contribution an occupation has on the greater economy — of a life sciences job exceeds that of generic jobs in health care by 40 percent.

Modeling conducted by the Center suggests a concerted effort to develop the region's life sciences industries compared to a 'business as usual' approach would yield an additional $13.1 billion in GDP and 73,000 jobs by 2036.

Historically, this industry has clustered on the East and West Coasts of the U.S., but recent efforts signal encouraging signs of progress.

Examples include the creation of TMC3 at the Texas Medical Center, a collaborative, multi-institution effort to build a life sciences research campus; the development of Houston's innovation corridor anchored by The Ion; and investment from the Cancer Prevention & Research Institute of Texas (CPRIT), a $6 billion state program to advance cancer research efforts and promote economic development.

Greater Houston has the potential to become the so-called Third Coast if we build on momentum that's starting to take hold.

Findings from our report suggest, however, that more work is needed to advance the life sciences.

This sector continues to grow rapidly—employment in this area rose by 37 percent from 2009 to 2019. Yet, the Center identified troubling data points, including that the number of people working in biotechnology and life sciences research and development declined by 13 percent from 2018 to 2008.

Our research identified several hurdles the region still faces in cultivating our still-nascent life sciences industry. First, Houston is still energy-dominant, with limited investment capital glowing to the life sciences. We must figure out how to attract venture capital, whether it be from Boston, Silicon Valley or elsewhere, to facilitate the growth of our existing biotechnology and life sciences firms and boost the rate of startup formation.

Second, Greater Houston continues to struggle with retaining life sciences talent, businesses and intellectual property. In some of the roughly 50 interviews the Center conducted with health care subject-matter experts, we heard that some businesses in the field relocate from Texas as soon as they begin growing. We believe the region should consider developing a cross-sector push for innovation that includes effectively scaling the research catalyzed by CPRIT.

By adopting a common vision and working together to grow Greater Houston's life sciences cluster, we can boost our economy and better position our health care sector to capitalize on the myriad new health care technologies that will emerge over the next couple decades.

------

Steven Scarborough is manager of strategic initiatives at Center for Houston's Future and the principal author of Houston's Economic Future: Health Care.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston's Ion District to expand with new research and tech space, The Arc

coming soon

Houston's Ion District is set to expand with the addition of a nearly 200,000-square-foot research and technology facility, The Arc at the Ion District.

Rice Real Estate Company and Lincoln Property Company are expected to break ground on the state-of-the-art facility in Q2 2026 with a completion target set for Q1 2028, according to a news release.

Rice University, the new facility's lead tenant, will occupy almost 30,000 square feet of office and lab space in The Arc, which will share a plaza with the Ion and is intended to "extend the district’s success as a hub for innovative ideas and collaboration." Rice research at The Arc will focus on energy, artificial intelligence, data science, robotics and computational engineering, according to the release.

“The Arc will offer Rice the opportunity to deepen its commitment to fostering world-changing innovation by bringing our leading minds and breakthrough discoveries into direct engagement with Houston’s thriving entrepreneurial ecosystem,” Rice President Reginald DesRoches said in the release. “Working side by side with industry experts and actual end users at the Ion District uniquely positions our faculty and students to form partnerships and collaborations that might not be possible elsewhere.”

Developers of the project are targeting LEED Gold certification by incorporating smart building automation and energy-saving features into The Arc's design. Tenants will have the opportunity to lease flexible floor plans ranging from 28,000 to 31,000 square feet with 15-foot-high ceilings. The property will also feature a gym, an amenity lounge, conference and meeting spaces, outdoor plazas, underground parking and on-site retail and dining.

Preleasing has begun for organizations interested in joining Rice in the building.

“The Arc at the Ion District will be more than a building—it will be a catalyst for the partnerships, innovations and discoveries that will define Houston’s future in science and technology,” Ken Jett, president of Rice Real Estate Company, added in the release. “By expanding our urban innovation ecosystem, The Arc will attract leading organizations and talent to Houston, further strengthening our city’s position as a hub for scientific and entrepreneurial progress.”

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

Houston team develops low-cost device to treat infants with life-threatening birth defect

infant innovation

A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies has developed a cost-effective treatment for infants born with gastroschisis, a congenital condition in which intestines and other organs are developed outside of the body.

The condition can be life-threatening in economically disadvantaged regions without access to equipment.

The Rice-developed device, known as SimpleSilo, is “simple, low-cost and locally manufacturable,” according to the university. It consists of a saline bag, oxygen tubing and a commercially available heat sealer, while mimicking the function of commercial silo bags, which are used in high-income countries to protect exposed organs and gently return them into the abdominal cavity gradually.

Generally, a single-use bag can cost between $200 and $300. The alternatives that exist lack structure and require surgical sewing. This is where the SimpleSilo comes in.

“We focused on keeping the design as simple and functional as possible, while still being affordable,” Vanshika Jhonsa said in a news release. “Our hope is that health care providers around the world can adapt the SimpleSilo to their local supplies and specific needs.”

The study was published in the Journal of Pediatric Surgery, and Jhonsa, its first author, also won the 2023 American Pediatric Surgical Association Innovation Award for the project. She is a recent Rice alumna and is currently a medical student at UTHealth Houston.

Bindi Naik-Mathuria, a pediatric surgeon at UTMB Health, served as the corresponding author of the study. Rice undergraduates Shreya Jindal and Shriya Shah, along with Mary Seifu Tirfie, a current Rice360 Global Health Fellow, also worked on the project.

In laboratory tests, the device demonstrated a fluid leakage rate of just 0.02 milliliters per hour, which is comparable to commercial silo bags, and it withstood repeated disinfection while maintaining its structure. In a simulated in vitro test using cow intestines and a mock abdominal wall, SimpleSilo achieved a 50 percent reduction of the intestines into the simulated cavity over three days, also matching the performance of commercial silo bags. The team plans to conduct a formal clinical trial in East Africa.

“Gastroschisis has one of the biggest survival gaps from high-resource settings to low-resource settings, but it doesn’t have to be this way,” Meaghan Bond, lecturer and senior design engineer at Rice360, added in the news release. “We believe the SimpleSilo can help close the survival gap by making treatment accessible and affordable, even in resource-limited settings.”
View All Listings